This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Trendlines Group Announces Co-development Agreement With Endo

TEL AVIV, Israel, November 13, 2012 /PRNewswire/ --

The Trendlines Group today announced it has entered into an R&D agreement aimed at co-developing novel medical devices and technologies within the areas of pain and urology, a strategic focus  of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP).  

The work will be conducted by Trendlines Labs, the technology development arm of The Trendlines Group.  Trendlines Labs is co-located with the Misgav Venture Accelerator - The Trendlines Group's incubator focused exclusively on the development of medtech innovations.  Misgav was named "Best Incubator" by Israel's Office of the Chief Scientist of the Ministry of Industry, Trade and Labor in 2010. Trendlines portfolio company Stimatix ( http://www.stimatix-gi.com) was named Israel's best start-up in 2012.

D. Todd Dollinger, Chairman and CEO of Trendlines, stated, "Our work with Endo furthers our market reach and is instrumental to our achieving our mission of creating and developing businesses to improve the human condition."  

Dr. Sujat Sukthankar, Vice President, Device R&D, at Endo said, "The Trendlines-Endo agreement is in line with our stated vision of sourcing innovation globally.  This partnership complements and bolsters our own internal innovation and product development efforts in the areas of pain and urology.  Through this partnership, we are excited to participate in the vibrant medical technology community in Israel. "  

Endo Health Solutions Inc. ( http://www.endo.com) is a U.S.-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through its operating companies: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike.

About The Trendlines Group

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs